ConductScience.org, home

Cell line · CVCL_1846

Papers32

2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.

PaperJournalYearHow we knowRetractedSource
The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma.MedComm (2020)2026Its Methods give the RRID and name the linePubMed
GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma.Cell Rep2026Its Methods give the RRID and name the linePubMed
Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma.Cancer Res2026Its Methods give the RRID and name the linePubMed
KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2.Nat Commun2025Its Methods give the RRID and name the linePubMed
Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer.Sci Adv2025Its Methods give the RRID and name the linePubMed
An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.J Immunother Cancer2025Its Methods give the RRID and name the linePubMed
Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time.JCI Insight2025Its Methods give the RRID and name the linePubMed
Tumor microenvironment acidosis favors pancreatic cancer stem cell properties and in vivo metastasis.iScience2025Its Methods give the RRID and name the linePubMed
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA.Mol Oncol2025Its Methods give the RRID and name the linePubMed
Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers.Clin Cancer Res2024Its Methods give the RRID and name the linePubMed
Non-canonical functions of SNAIL drive context-specific cancer progression.Nat Commun2023Its Methods give the RRID and name the linePubMed
ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.Cancer Res Commun2022Its Methods give the RRID and name the linePubMed
Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma.Cancer Metab2022Its Methods give the RRID and name the linePubMed
Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis.Cell Rep2021Its Methods give the RRID and name the linePubMed
Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation.Elife2020Its Methods give the RRID and name the linePubMed
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.Nat Commun2019Cellosaurus cites itPubMed
Next-generation characterization of the Cancer Cell Line Encyclopedia.Nature2019Cellosaurus cites itPubMed
An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines.Cancer Res2019Cellosaurus cites itPubMed
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.Cancer Cell2017Cellosaurus cites itPubMed
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.Genome Med2015Cellosaurus cites itPubMed

cell-lines-2026-11-14-0.1.0

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_1846/papers